Which has better earnings and valuation, IRMD or SGHT?

iRadimed has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 13.78 $22.48M $1.79 50.43 Sight Sciences $77.36M 5.48 -$38.43M -$0.56 N/A

Is IRMD or SGHT more profitable?

iRadimed has a net margin of 26.70% compared to Sight Sciences' net margin of -35.69%. iRadimed's return on equity of 23.45% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 26.70% 23.45% 20.36% Sight Sciences -35.69% -43.39% -22.86%

Does the media favor IRMD or SGHT?

In the previous week, Sight Sciences had 7 more articles in the media than iRadimed. MarketBeat recorded 14 mentions for Sight Sciences and 7 mentions for iRadimed. Sight Sciences' average media sentiment score of 0.61 beat iRadimed's score of 0.19 indicating that Sight Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Sight Sciences 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger valuation and earnings, SGHT or BVS?

Bioventus has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sight Sciences $77.36M 5.48 -$38.43M -$0.56 N/A Bioventus $568.09M 2.05 $22.73M $0.77 18.13

Is SGHT or BVS more profitable?

Bioventus has a net margin of 9.36% compared to Sight Sciences' net margin of -35.69%. Bioventus' return on equity of 28.08% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -35.69% -43.39% -22.86% Bioventus 9.36% 28.08% 9.82%

Does the media favor SGHT or BVS?

In the previous week, Bioventus had 3 more articles in the media than Sight Sciences. MarketBeat recorded 17 mentions for Bioventus and 14 mentions for Sight Sciences. Bioventus' average media sentiment score of 0.65 beat Sight Sciences' score of 0.61 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Bioventus 5 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DRTS or SGHT?

In the previous week, Sight Sciences had 5 more articles in the media than Alpha Tau Medical. MarketBeat recorded 14 mentions for Sight Sciences and 9 mentions for Alpha Tau Medical. Sight Sciences' average media sentiment score of 0.61 beat Alpha Tau Medical's score of 0.60 indicating that Sight Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Tau Medical 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sight Sciences 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer PRCT or SGHT?

In the previous week, PROCEPT BioRobotics had 39 more articles in the media than Sight Sciences. MarketBeat recorded 53 mentions for PROCEPT BioRobotics and 14 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 0.61 beat PROCEPT BioRobotics' score of 0.02 indicating that Sight Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 5 Very Positive mention(s) 2 Positive mention(s) 41 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Sight Sciences 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better valuation & earnings, SGHT or INMD?

InMode has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sight Sciences $77.36M 5.48 -$38.43M -$0.56 N/A InMode $370.49M 2.36 $93.83M $1.23 12.35

Is SGHT or INMD more profitable?

InMode has a net margin of 20.69% compared to Sight Sciences' net margin of -35.69%. InMode's return on equity of 11.99% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Sight Sciences -35.69% -43.39% -22.86% InMode 20.69% 11.99% 10.60%

Does the media favor SGHT or INMD?

In the previous week, Sight Sciences had 8 more articles in the media than InMode. MarketBeat recorded 14 mentions for Sight Sciences and 6 mentions for InMode. InMode's average media sentiment score of 0.67 beat Sight Sciences' score of 0.61 indicating that InMode is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive InMode 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Sight Sciences (SGHT) Competitors

$7.70 +0.23 (+3.08%)

As of 04:00 PM Eastern

Compare

SGHT vs. IRMD, BVS, DRTS, PRCT, and INMD

Should you buy Sight Sciences stock or one of its competitors? Sight Sciences's main competitors and comparable companies include iRadimed (IRMD), Bioventus (BVS), Alpha Tau Medical (DRTS), PROCEPT BioRobotics (PRCT), and InMode (INMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Sight Sciences compare to iRadimed?

iRadimed (NASDAQ:IRMD) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

iRadimed has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market.

iRadimed presently has a consensus target price of $120.00, indicating a potential upside of 32.93%. Sight Sciences has a consensus target price of $7.88, indicating a potential upside of 2.27%. Given iRadimed's stronger consensus rating and higher possible upside, equities analysts clearly believe iRadimed is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

92.3% of iRadimed shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 34.6% of iRadimed shares are held by company insiders. Comparatively, 30.4% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Sight Sciences had 7 more articles in the media than iRadimed. MarketBeat recorded 14 mentions for Sight Sciences and 7 mentions for iRadimed. Sight Sciences' average media sentiment score of 0.61 beat iRadimed's score of 0.19 indicating that Sight Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sight Sciences	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

iRadimed has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.78	$22.48M	$1.79	50.43
Sight Sciences	$77.36M	5.48	-$38.43M	-$0.56	N/A

iRadimed has a net margin of 26.70% compared to Sight Sciences' net margin of -35.69%. iRadimed's return on equity of 23.45% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
Sight Sciences	-35.69%	-43.39%	-22.86%

Summary

iRadimed beats Sight Sciences on 13 of the 17 factors compared between the two stocks.

How does Sight Sciences compare to Bioventus?

Sight Sciences (NASDAQ:SGHT) and Bioventus (NASDAQ:BVS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Bioventus has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	5.48	-$38.43M	-$0.56	N/A
Bioventus	$568.09M	2.05	$22.73M	$0.77	18.13

In the previous week, Bioventus had 3 more articles in the media than Sight Sciences. MarketBeat recorded 17 mentions for Bioventus and 14 mentions for Sight Sciences. Bioventus' average media sentiment score of 0.65 beat Sight Sciences' score of 0.61 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Bioventus	5 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has a net margin of 9.36% compared to Sight Sciences' net margin of -35.69%. Bioventus' return on equity of 28.08% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-35.69%	-43.39%	-22.86%
Bioventus	9.36%	28.08%	9.82%

Sight Sciences presently has a consensus price target of $7.88, suggesting a potential upside of 2.27%. Bioventus has a consensus price target of $16.25, suggesting a potential upside of 16.40%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 30.4% of Sight Sciences shares are held by insiders. Comparatively, 33.5% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sight Sciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Summary

Bioventus beats Sight Sciences on 14 of the 17 factors compared between the two stocks.

How does Sight Sciences compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTS) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Sight Sciences had 5 more articles in the media than Alpha Tau Medical. MarketBeat recorded 14 mentions for Sight Sciences and 9 mentions for Alpha Tau Medical. Sight Sciences' average media sentiment score of 0.61 beat Alpha Tau Medical's score of 0.60 indicating that Sight Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Tau Medical	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sight Sciences	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Alpha Tau Medical has a net margin of 0.00% compared to Sight Sciences' net margin of -35.69%. Sight Sciences' return on equity of -43.39% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-73.23%	-52.90%
Sight Sciences	-35.69%	-43.39%	-22.86%

2.7% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by insiders. Comparatively, 30.4% of Sight Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sight Sciences has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.67	N/A
Sight Sciences	$77.36M	5.48	-$38.43M	-$0.56	N/A

Alpha Tau Medical has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market.

Alpha Tau Medical presently has a consensus target price of $12.60, suggesting a potential downside of 7.35%. Sight Sciences has a consensus target price of $7.88, suggesting a potential upside of 2.27%. Given Sight Sciences' higher possible upside, analysts plainly believe Sight Sciences is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Sight Sciences beats Alpha Tau Medical on 11 of the 14 factors compared between the two stocks.

How does Sight Sciences compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

PROCEPT BioRobotics has a net margin of -32.53% compared to Sight Sciences' net margin of -35.69%. PROCEPT BioRobotics' return on equity of -30.62% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%
Sight Sciences	-35.69%	-43.39%	-22.86%

Sight Sciences has lower revenue, but higher earnings than PROCEPT BioRobotics. Sight Sciences is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	4.01	-$95.57M	-$1.94	N/A
Sight Sciences	$77.36M	5.48	-$38.43M	-$0.56	N/A

In the previous week, PROCEPT BioRobotics had 39 more articles in the media than Sight Sciences. MarketBeat recorded 53 mentions for PROCEPT BioRobotics and 14 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 0.61 beat PROCEPT BioRobotics' score of 0.02 indicating that Sight Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	5 Very Positive mention(s)	2 Positive mention(s)	41 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sight Sciences	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

PROCEPT BioRobotics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market.

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 30.4% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

PROCEPT BioRobotics presently has a consensus target price of $28.00, suggesting a potential upside of 28.97%. Sight Sciences has a consensus target price of $7.88, suggesting a potential upside of 2.27%. Given PROCEPT BioRobotics' higher possible upside, equities analysts clearly believe PROCEPT BioRobotics is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.19
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

PROCEPT BioRobotics beats Sight Sciences on 9 of the 17 factors compared between the two stocks.

How does Sight Sciences compare to InMode?

Sight Sciences (NASDAQ:SGHT) and InMode (NASDAQ:INMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

In the previous week, Sight Sciences had 8 more articles in the media than InMode. MarketBeat recorded 14 mentions for Sight Sciences and 6 mentions for InMode. InMode's average media sentiment score of 0.67 beat Sight Sciences' score of 0.61 indicating that InMode is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
InMode	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

InMode has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	5.48	-$38.43M	-$0.56	N/A
InMode	$370.49M	2.36	$93.83M	$1.23	12.35

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 30.4% of Sight Sciences shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sight Sciences currently has a consensus target price of $7.88, indicating a potential upside of 2.27%. InMode has a consensus target price of $16.00, indicating a potential upside of 5.33%. Given InMode's higher probable upside, analysts plainly believe InMode is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InMode has a net margin of 20.69% compared to Sight Sciences' net margin of -35.69%. InMode's return on equity of 11.99% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-35.69%	-43.39%	-22.86%
InMode	20.69%	11.99%	10.60%

Sight Sciences has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market. Comparatively, InMode has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market.

Summary

InMode beats Sight Sciences on 10 of the 16 factors compared between the two stocks.

Get Sight Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGHT vs. The Competition

Export

Metric	Sight Sciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$424.19M	$5.79B	$7.06B	$12.95B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	-13.75	24.71	269.75	24.74
Price / Sales	5.48	67.44	652.34	108.60
Price / Cash	N/A	33.55	28.89	37.44
Price / Book	6.36	6.21	11.27	6.42
Net Income	-$38.43M	$147.87M	$3.45B	$347.12M
7 Day Performance	39.24%	3.40%	3.57%	2.48%
1 Month Performance	44.74%	1.67%	-0.58%	-1.04%
1 Year Performance	81.60%	6.26%	77.53%	23.22%

Sight Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGHT Sight Sciences	1.6057 of 5 stars	$7.70 +3.1%	$7.88 +2.3%	+76.2%	$424.19M	$77.36M	N/A	210	Earnings Report Analyst Forecast
IRMD iRadimed	2.5947 of 5 stars	$93.13 +1.7%	$120.00 +28.9%	+32.3%	$1.17B	$83.81M	52.03	110	Analyst Downgrade
BVS Bioventus	4.318 of 5 stars	$13.42 -0.4%	$14.75 +9.9%	+104.2%	$1.13B	$568.09M	32.73	1,200	Earnings Report
DRTS Alpha Tau Medical	1.6274 of 5 stars	$13.08 +9.7%	$12.60 -3.7%	+287.6%	$1.08B	N/A	N/A	80	News Coverage Earnings Report
PRCT PROCEPT BioRobotics	3.4277 of 5 stars	$18.28 -0.5%	$33.45 +83.0%	-46.9%	$1.05B	$308.05M	N/A	430	Trending News Earnings Report Insider Trade Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGHT) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sight Sciences (SGHT) Competitors

SGHT vs. IRMD, BVS, DRTS, PRCT, and INMD

How does Sight Sciences compare to iRadimed?

Summary

How does Sight Sciences compare to Bioventus?

Summary

How does Sight Sciences compare to Alpha Tau Medical?

Summary

How does Sight Sciences compare to PROCEPT BioRobotics?

Summary

How does Sight Sciences compare to InMode?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGHT vs. The Competition

Sight Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sight Sciences (SGHT) Competitors

SGHT vs. IRMD, BVS, DRTS, PRCT, and INMD

How does Sight Sciences compare to iRadimed?

Which has more risk and volatility, IRMD or SGHT?

Do analysts rate IRMD or SGHT?

Do institutionals and insiders believe in IRMD or SGHT?

Does the media favor IRMD or SGHT?

Which has better earnings and valuation, IRMD or SGHT?

Is IRMD or SGHT more profitable?

Summary

How does Sight Sciences compare to Bioventus?

Which has stronger valuation and earnings, SGHT or BVS?

Does the media favor SGHT or BVS?

Is SGHT or BVS more profitable?

Do analysts recommend SGHT or BVS?

Do institutionals and insiders hold more shares of SGHT or BVS?

Which has more volatility & risk, SGHT or BVS?

Summary

How does Sight Sciences compare to Alpha Tau Medical?

Does the media refer more to DRTS or SGHT?

Is DRTS or SGHT more profitable?

Do insiders & institutionals have more ownership in DRTS or SGHT?

Which has preferable earnings and valuation, DRTS or SGHT?

Which has more risk and volatility, DRTS or SGHT?

Do analysts rate DRTS or SGHT?

Summary

How does Sight Sciences compare to PROCEPT BioRobotics?

Is PRCT or SGHT more profitable?

Which has stronger valuation and earnings, PRCT or SGHT?

Does the media prefer PRCT or SGHT?

Which has more risk & volatility, PRCT or SGHT?

Do institutionals & insiders have more ownership in PRCT or SGHT?

Do analysts rate PRCT or SGHT?

Summary

How does Sight Sciences compare to InMode?

Does the media favor SGHT or INMD?

Which has better valuation & earnings, SGHT or INMD?

Do institutionals & insiders hold more shares of SGHT or INMD?

Do analysts rate SGHT or INMD?

Is SGHT or INMD more profitable?

Which has more risk and volatility, SGHT or INMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGHT vs. The Competition

Sight Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools